You are here: Industry Insights > Foresee

News List

Foresee announces potential new COVID-19 drug firstwordpharma
July 07, 2021
Foresee Pharmaceuticals' drug FP-025 to treat acute respiratory distress syndrome in COVID-19 patients has been given a nod from an independent data monitoring committee (IDMC) in the US, reported the Taipei Times.
Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS prnasia
March 29, 2021
Foresee Pharmaceuticals Co., Ltd., today announced the initiation of patient dosing in the Phase 2/3 clinical trial of FP-025, its highly selective oral MMP-12 inhibitor, in adult patients with severe to critical COVID-19 with ...
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States prnasia
March 05, 2021
Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with Intas Pharmaceuticals for the US commercialization of Foresee's novel FP-001 program, Leuprolide Mesylate Injectable Suspension (LMIS) ready-to-use ...
Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi(TM) in China prnasia
November 18, 2020
Foresee Pharmaceuticals announced that it has entered into an exclusive license agreement with GenScience Pharmaceuticals - a wholly-owned subsidiary of Changchun High-Tech Industry (Group) Co., Ltd. - for the commercialization of Foresee's novel FP-001..
Foresee pharmaceuticals announces key executive appointments pharmaasia
April 24, 2017
Foresee Pharmaceuticals announced the appointments of two key executives with strong medical, scientific and drug development experience and expertise.
Foresee announces successful completion of scientific advice discussions with German Federal Institu pharmaasia
March 02, 2017
Foresee announced conclusion of its scientific advice discussions with German BfArM on Marketing Authorization Application submission of FP-001
Foresee pharmaceuticals announces top-line results from phase 3 registration study in advanced prost pharmaasia
February 21, 2017
Foresee Pharmaceuticals announced top-line result of FP-001 50mg phase 3 clinical trial, an open-label study in subjects with Advanced Prostate Carcinoma